Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Cybersecurity ETF vs Quest Diagnostics Inc — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $100.08, while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc pays a 1.45% dividend while First Trust NASDAQ Cybersecurity ETF pays none. Which is the better fit depends on your goals.
| CIBR | DGX | |
|---|---|---|
52-Week High | $100.60 | $238.50 |
52-Week Low | $60.74 | $173.49 |
Market Cap | — | $26.21B |
Sector | — | Health |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIBR trades at $100.39, down 0.21% on the day, with a bullish technical signal driven by moving averages but overbought RSI readings. The ETF benefits from strong cybersecurity spending trends, with global expenditures exceeding $300 billion in 2026 (Gartner, 2026-06-04), and has outperformed the S&P 500 year-to-date. Recent institutional activity shows mixed signals, with Bank of America reducing its stake while First Trust Advisors increased its position.
Outlook remains positive due to secular growth in cybersecurity demand, though high RSI levels suggest near-term consolidation risks. Investment opportunity lies in AI-driven security needs, but concentration in tech and valuation sensitivity are key risks for investors.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
